• Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
  • The company has also announced a new chronic kidney disease research program
  • CEO Chris Moreau sat down with Shoran Devi to discuss the news
  • Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
  • Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.

Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.

The company has also announced a new chronic kidney disease research program.

CEO Chris Moreau sat down with Shoran Devi to discuss the news.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.

More From The Market Online

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.
stock market down

@ the Bell: Industrials weakness snaps TSX win streak

Industrials led decliners, followed by financials, to snap the TSX’s five-day win streak while energy, utilities and mining provided gains.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.